Literature DB >> 23442303

Genetic changes with prognostic value in histologically benign meningiomas.

Sandra Barbera1, Teresa San Miguel, Rosario Gil-Benso, Lisandra Muñoz-Hidalgo, Pedro Roldan, Jose Gonzalez-Darder, Miguel Cerda-Nicolas, Concha Lopez-Gines.   

Abstract

Meningiomas add up to 25% of intracranial tumors. Although the majority is considered histologically benign, the prediction of their potential aggressiveness is still unclear. We studied the histopathology and aberrations of chromosomes 1p, 14, and 22 by FISH (fluorescence in situ hybridization) in histologically benign meningiomas of 70 patients for the purpose of defining the prognostic value of these alterations in tumoral progression and the risk of recurrence. According to the WHO histopathological criteria, the study set comprised 53 benign, 11 atypical, and 6 anaplastic meningiomas. In benign meningiomas, 25% of the cases displayed a normal karyotype, isolated monosomy 22 (36%), monosomy 22 + 1p deletion (14%), 1p deletion (10%), monosomy 22 + 14q deletion (5%), monosomy 22 + 1p deletion + 14q deletion (5%), or other alterations (5%). Grade II meningiomas presented losses in chromosome 14 in most of the cases (67%), and Grade III meningiomas showed alterations in chromosome 14 in all patients. We observed an overall relapse rate of 31%: recurrence was observed in 19% of Grade I meningiomas, 64% of Grade II, and 83% of Grade III. 9 out of 10 recurrent cases revealed abnormalities in chromosomes 1 and 14, which was a notably higher incidence compared to the series of tumors without relapse. Thus, benign meningiomas with cytogenetic alterations in chromosomes 1p and 14 may be more closely related to atypical meningiomas than benign meningiomas without these alterations, especially in terms of recurrence risk.

Entities:  

Mesh:

Year:  2013        PMID: 23442303     DOI: 10.5414/NP300580

Source DB:  PubMed          Journal:  Clin Neuropathol        ISSN: 0722-5091            Impact factor:   1.368


  8 in total

1.  Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development.

Authors:  Elias A El-Habr; Georgia Levidou; Eleni-Andriana Trigka; Joanna Sakalidou; Christina Piperi; Ilenia Chatziandreou; Anastasia Spyropoulou; Rigas Soldatos; Georgia Tomara; Kalliopi Petraki; Vassilis Samaras; Athanasios Zisakis; Vassilis Varsos; George Vrettakos; Efstathios Boviatsis; Efstratios Patsouris; Angelica A Saetta; Penelope Korkolopoulou
Journal:  Virchows Arch       Date:  2014-08-22       Impact factor: 4.064

2.  Combined Extradural and Intradural Pterional Transzygomatic Approach to Large Sphenoid Wing Meningiomas. Operative Technique and Surgical Results.

Authors:  José M González-Darder
Journal:  J Neurol Surg B Skull Base       Date:  2018-08-21

3.  Molecular progression in unusual recurrent non-pediatric intracranial clear cell meningioma.

Authors:  B Domingo-Arrué; R Gil-Benso; J Megías; L Navarro; T San-Miguel; L Muñoz-Hidalgo; C López-Ginés; M Cerdá-Nicolás
Journal:  Curr Oncol       Date:  2017-06-27       Impact factor: 3.677

Review 4.  Synthesizing Molecular and Immune Characteristics to Move Beyond WHO Grade in Meningiomas: A Focused Review.

Authors:  Nivedha V Kannapadi; Pavan P Shah; Dimitrios Mathios; Christopher M Jackson
Journal:  Front Oncol       Date:  2022-05-31       Impact factor: 5.738

5.  Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype.

Authors:  Patrícia Henriques Domingues; Pablo Sousa; Álvaro Otero; Jesus Maria Gonçalves; Laura Ruiz; Catarina de Oliveira; Maria Celeste Lopes; Alberto Orfao; Maria Dolores Tabernero
Journal:  Neuro Oncol       Date:  2014-02-16       Impact factor: 12.300

Review 6.  Genetic/molecular alterations of meningiomas and the signaling pathways targeted.

Authors:  Patrícia Domingues; María González-Tablas; Álvaro Otero; Daniel Pascual; Laura Ruiz; David Miranda; Pablo Sousa; Jesús María Gonçalves; María Celeste Lopes; Alberto Orfao; María Dolores Tabernero
Journal:  Oncotarget       Date:  2015-05-10

7.  Matched Paired Primary and Recurrent Meningiomas Points to Cell-Death Program Contributions to Genomic and Epigenomic Instability along Tumor Progression.

Authors:  Teresa San-Miguel; Javier Megías; Daniel Monleón; Lara Navarro; Lisandra Muñoz-Hidalgo; Carmina Montoliu; Marina Meri; Pedro Roldán; Miguel Cerdá-Nicolás; Concha López-Ginés
Journal:  Cancers (Basel)       Date:  2022-08-19       Impact factor: 6.575

8.  WHO Grade I Meningioma Recurrence: Identifying High Risk Patients Using Histopathological Features and the MIB-1 Index.

Authors:  Alexander F Haddad; Jacob S Young; Ishan Kanungo; Sweta Sudhir; Jia-Shu Chen; David R Raleigh; Stephen T Magill; Michael W McDermott; Manish K Aghi
Journal:  Front Oncol       Date:  2020-08-28       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.